Growth Strategy Director, Strategic Program Management
HumanaFull Time
Expert & Leadership (9+ years)
Candidates must possess a Bachelor's degree in Natural Science, Pharmacy, or a related field. A minimum of 15 years of experience in the biopharma/pharmaceutical industry is required, including at least ten years of people and team management and a minimum of 5 years of leadership experience in driving business transformations. A thorough understanding of GxP regulatory requirements, strong program/project management experience with a proven record of managing cross-functional programs, and the ability to oversee multiple projects are essential. Strategic thinking capability with the ability to make and act on decisions while balancing speed, quality, and risk is necessary, along with demonstrated influencing skills with senior levels over multiple disciplines, and excellent teamwork, interpersonal, and communication/listening skills.
The Senior Director will develop and execute the strategic roadmap for Lifecycle Management and Operational Controls within the Quality Management System (QMS) to achieve long-term strategic goals. Key responsibilities include influencing and aligning QMS focus areas with senior leaders, ensuring the end-to-end flow of QMS processes, partnering with senior leaders to develop and execute a rolling 3-5 year strategy, and ensuring core competencies are built within the team. The role involves providing input to enhance process and the BMS Quality strategy, maintaining and prioritizing continuous improvement projects, identifying, mitigating, and communicating critical risks, and partnering with local sites to ensure document management capabilities and QMS compliance. Additionally, the Senior Director will develop and implement metrics, associated targets, and reporting mechanisms to monitor performance and champion a Quality mindset and Culture of Quality.
Develops and delivers biopharmaceutical medicines
Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.